DEVELOPMENT OF MAPATUMUMAB, A FULLY HUMAN AGONISTIC MONOCLONAL ANTIBODY WHICH TARGETS AND ACTIVATES THE TRAIL-RECEPTOR-1

被引：0
|
作者：
Gallant, G. J. A. [1 ]
机构：
[1] Human Genome Sci, Rockville, MD USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [21] TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
    Tamada, Taro
    Shinmi, Daisuke
    Ikeda, Masahiro
    Yonezawa, Yasushi
    Kataoka, Shiro
    Kuroki, Ryota
    Mori, Eiji
    Motoki, Kazuhiro
    SCIENTIFIC REPORTS, 2015, 5
  • [22] HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
    Pukac, L
    Kanakaraj, P
    Humphreys, R
    Alderson, R
    Bloom, M
    Sung, C
    Riccobene, T
    Johnson, R
    Fiscella, M
    Mahoney, A
    Carrell, J
    Boyd, E
    Yao, XT
    Zhang, L
    Zhong, L
    von Kerczek, A
    Shepard, L
    Vaughan, T
    Edwards, B
    Dobson, C
    Salcedo, T
    Albert, V
    BRITISH JOURNAL OF CANCER, 2005, 92 (08) : 1430 - 1441
  • [23] HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
    L Pukac
    P Kanakaraj
    R Humphreys
    R Alderson
    M Bloom
    C Sung
    T Riccobene
    R Johnson
    M Fiscella
    A Mahoney
    J Carrell
    E Boyd
    X T Yao
    L Zhang
    L Zhong
    A von Kerczek
    L Shepard
    T Vaughan
    B Edwards
    C Dobson
    T Salcedo
    V Albert
    British Journal of Cancer, 2005, 92 : 1430 - 1441
  • [24] Agonistic antibody to TRAIL-R1 (Mapatumumab) and low dose Bortezomib induce apoptosis in multiple myeloma while preserving dendritic cell function
    Neeson, Paul
    Chen, Karen
    Tai, Tsin
    Shin, Amanda
    Tainton, Kellie
    Fielding, Kate
    Davis, Joanne
    Prince, H.
    Humphreys, Robin
    Ritchie, David
    CANCER RESEARCH, 2009, 69
  • [25] Results of a phase 2 trial of HGS-ETR1 (Agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Younes, A
    Vose, JM
    Zelenetz, AD
    Smith, MR
    Burris, H
    Ansell, S
    Klein, J
    Kumm, E
    Czuczman, M
    BLOOD, 2005, 106 (11) : 146A - 147A
  • [26] Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
    Tolcher, Anthony W.
    Mita, Monica
    Meropol, Neal J.
    von Mehren, Margaret
    Patnaik, Amita
    Padavic, Kristin
    Hill, Monique
    Mays, Theresa
    McCoy, Therese
    Fox, Norma Lynn
    Halpern, Wendy
    Corey, Alfred
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) : 1390 - 1395
  • [27] HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.
    Hirte, HW
    Hotte, SJ
    Chen, EX
    Siu, L
    Le, LH
    Lo, L
    MacLean, M
    Iacobucci, A
    Fox, NL
    Oza, AM
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9104S - 9104S
  • [28] A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC
    Von Pawel, J.
    Harvey, J. H.
    Spigel, D. R.
    Dediu, M.
    Reck, M.
    Cebotaru, C. L.
    Kumm, E.
    Gallant, G.
    Fox, N.
    Camidge, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [29] Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
    Yang, XD
    Jia, XC
    Corvalan, JRF
    Wang, P
    Davis, CG
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 38 (01) : 17 - 23
  • [30] In vitro synergistic anti-tumor activity by targeting TRAIL-R1 and CD20 antigen by combining HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) and rituximab monoclonal antibody against non-Hodgkin's lymphoma cells (NHL).
    Czuczman, MS
    Maddipatla, S
    Knight, J
    Hernandez-Ilizaliturri, FJ
    BLOOD, 2005, 106 (11) : 425A - 425A
12345